HRS4R
Vull donar

GEMMA OSCA GELIS

Firma
GEMMA OSCA-GELIS
Posició
Investigador/a Post-doctoral – R2
Investigadors/es Post-doctorals – R2

Projectes

Codi oficial: 6822ZB3KJ Data inici: 01/01/2022 Data fi: 30/06/2025 Investigador/a principal: DAVID GALLARDO GIRALT Organisme finançador: AGÈNCIA DE GESTIÓ UNIVERSITARIS I RECERCA

Publicacions

Gonzalez-Montes, Y, Osca-Gelis, G, Rodriguez-Romanos, R, Villavicencio, A, González-Bártulos, M, Llopis, F, Clapes, V, Oriol, A, Sureda, A, Escoda, L, Sarrà, J, Garzó, A, Lloveras, N, Gómez, B, Granada, I, Gallardo, D

CD200 genotype is associated with clinical outcome of patients with multiple myeloma

Frontiers in Immunology, 2024, 15, 1252445-1252445 dx.doi.org/10.3389/fimmu.2024.1252445
Huguet, M, Casabella, L, Suero, M, Blanco, N, Ros, T, Mart n, JA, Vigo, A, Carrascosa, T, Jim nez, C, Kara, M, Ferreiro, JJ, L pez, J, de Heredia, CD, L pez, C, Gil, E, Albo, C, Arcarons, J, Perla, A, Salcedo, I, Escoda, L, Blanquer, M, Hernani, R, Espana, L, Gonz lez, S, Navarro, J, Mu oz, C, Alacid, M, Chamorro, C, G mez, C, Mart n, MP, Rodr guez, AM, S nchez, P, Callejas, M, Monta o, JM, Osca, G, Arzuaga, J, Gonz lez, MS, Morgades, M, Torrent, A, Jim nez, MJ

EBMT REGISTRY: HOW IS IT CARRIED OUT IN THE SPANISH TRANSPLANT CENTRES? A STUDY ON BEHALF OF SPANISH HEMATOPOIETIC STEM CELL TRANSPLANTATION GROUP (GETH-TC)

BONE MARROW TRANSPLANTATION, 2024, 59, 743-744
Auñón C, Sanvisens A, Turon E, Vidal-Vila A, Puigdemont M, Osca-Gelis G, Eraso A, Marcos-Gragera R

Time trends and survival of marginal zone lymphoma over 25 years in Girona, Spain (1994-2018)

CANCER MEDICINE, 2023, 12, 12343-12353 dx.doi.org/10.1002/cam4.5935
Gonzalez-Montes Y, Rodriguez-Romanos R, Villavicencio A, Osca-Gelis G, González-Bártulos M, Llopis F, Clapes V, Oriol A, Sureda A, Escoda L, Sarrà J, Garzó A, Lloveras N, Díez I, Granada I, Gallardo D

Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma

Frontiers in Immunology, 2023, 14, 1158105-1158105 dx.doi.org/10.3389/fimmu.2023.1158105
Bosch-Barrera, J, Teixidor, E, Sanvisens, A, Puigdemont, M, Trallero, J, Vila, AV, Osca, G, Roberte, MV, Priego, N, Sais, E, Martínez, AH, Ortega, JS, Cuyàs, E, Verdura, S, Puig, J, Pineda, V, Martí-Navas, M, Calvo, A, Menendez, JA, Marcos-Gragera, R, Valiente, M

Using Silibinin to Target STAT3-Positive Reactive Astrocytes for the Treatment of NSCLC Brain Metastases

JOURNAL OF THORACIC ONCOLOGY, 2023, 18, 426-427
Díaz-Santa J, Rodríguez-Romanos R, Coll R, Osca G, Pratcorona M, González-Bártulos M, Garrido A, Angona A, Talarn C, Tormo M, Arnan M, Vives S, Salamero O, Tuset E, Lloveras N, Díez I, Zamora L, Bargay J, Sampol A, Cruz D, Vila J, Sitges M, Garcia A, Vall-Llovera F, Esteve J, Sierra J, Gallardo D

5 '-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics

EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109, 755-764 dx.doi.org/10.1111/ejh.13862
Rubió-Casadevall J, Carbó-Bagué A, Puigdemont M, Osca-Gelis G, Oliveras G, Vilar-Coromina N, Ferrer-Fabrega B, Urban A, Llobet-Roma M, Martín-Romero F, Perez-Bueno F, Marcos-Gragera R

Population-based analysis of the prevalence of BRAF mutation in patients diagnosed with cutaneous melanoma and its significance as a prognostic factor

EUROPEAN JOURNAL OF DERMATOLOGY, 2021, 31, 616-622 dx.doi.org/10.1684/ejd.2021.4136
Díaz-Santa J, Rodríguez-Romanos R, Osca G, Pratcorona M, Garrido A, Coll R, Moret C, Escoda L, Tormo M, Heras I, Arnan M, Vives S, Salamero O, Lloveras N, Bargay J, Sampol A, Cruz D, Garcia A, Quiñones T, Esteve J, Sierra J, Gallardo D

UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy

Leukemia, 2020, 34, 2925-2933 dx.doi.org/10.1038/s41375-020-0784-2
Fort Culillas, R., Carmona Garcia, C., Osca Geli, G., Marcos-Gragera, R., Puigdemont Guinart, M., Biarnes Costa, J., Lopez-Ben, S., Garcia Velasco, A., Guardeno Sanchez, R.

Incidence and survival of pancreatic neuroendocrine tumours in Girona, Spain

ANNALS OF ONCOLOGY, 2020, 31, 169-169 dx.doi.org/10.1016/j.annonc.2020.04.325
Solans M, Osca-Gelis G, Comas R, Roncero JM, Gallardo D, Marcos-Gragera R, Saez M

Challenges in assessing the real incidence of chronic lymphocytic leukemia: 16 years of epidemiological data from the province of Girona, Spain

CANCER CAUSES & CONTROL, 2018, 29, 379-382 dx.doi.org/10.1007/s10552-018-1004-5

Formulari de contacte

Coneix l’IDIBGI!

menu